Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data
Our findings align with clinical observations, highlighting the emergence of previously unreported AE signals associated with MPA and their demographic and TTO characteristics. Further pharmaco-epidemiological studies are required to substantiate these observations.
Authors
- Weilan Liu
- Zeqing Du (ORCID: https://orcid.org/0009-0005-1267-8438)
- Yanan Ren (ORCID: https://orcid.org/0000-0001-9586-3690)
- Shixia Zhao
- Ren Xu
- Luyang Su
Institutions
- Hebei Medical University (CN)
- Second Hospital of Hebei Medical University (CN)
- Hebei General Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-12-11
- DOI
- https://doi.org/10.3389/fphar.2024.1491032
- Citations
- 3
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 1.05